Share on LinkedInShare on LinkedIn

ARTICLE · 05 APRIL 2016

Sequenom Asks The Supreme Court To Clarify The Limits On Section 101

BakerHostetler
BakerHostetler
Contributor
BakerHostetler

BakerHostetler

Recognized as an innovator and one of the top firms for client service, BakerHostetler helps...

View firm profile
Explore more from BakerHostetler

On March 21, 2016, Sequenom filed a writ of certiorari with the U.S. Supreme Court, asking the Court to provide clarification regarding the limits of 35 U.S.C §101 as it relates to patent eligibility of diagnostic tests.

United StatesIntellectual Property

On March 21, 2016, Sequenom filed a writ of certiorari with the U.S. Supreme Court, asking the Court to provide clarification regarding the limits of 35 U.S.C §101 as it relates to patent eligibility of diagnostic tests. Sequenom's petition presents the following question:

Whether a novel method is patent-eligible where:

(1) a researcher is the first to discover a natural phenomenon;

(2) that unique knowledge motivates him to apply a new combination of known techniques to that discovery; and

(3) he thereby achieves a previously impossible result without preempting other uses of the discovery?

Petition for Writ of Certiorari at i, Sequenom, Inc., v. Ariosa Diagnostic, Inc., No. 15-1182 (March 21, 2016). The petition offers the Court the opportunity to loosen the seemingly universal prohibition against diagnostic method claims set forth in Mayo Collaborative Servs. v. Prometheus Labs., 132 S. Ct. 1289 (2012).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from